Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
Karyn A GoodmanFang-Shu OuNathan C HallTanios Bekaii-SaabBriant FruthErin TwohyMichael O MeyersMichelle C SalazarKisha MitchellWendy L FrankelDonna NiedzwieckiAnne M NoonanYelena Y JanjigianPaul J ThurmesAlan P VenookJeffrey A MeyerhardtEileen M O'ReillyDavid H IlsonPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Early response assessment using PET imaging as a biomarker to individualize therapy for patients with esophageal and esophagogastric junction adenocarcinoma was effective, improving pCR rates in PET nonresponders. PET responders to induction FOLFOX who continued on FOLFOX during chemoradiation achieved a promising 5-year overall survival of 53%.